Unique ID issued by UMIN | UMIN000002824 |
---|---|
Receipt number | R000002968 |
Scientific Title | A phase II trial of combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer. |
Date of disclosure of the study information | 2009/12/03 |
Last modified on | 2015/10/11 13:11:25 |
A phase II trial of combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer.
Combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer.
A phase II trial of combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer.
Combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer.
Japan |
unresectable gallbladder cancer
Hepato-biliary-pancreatic medicine |
Malignancy
NO
The purpose of this study is to evaluate clinical efficacy and safety of the combination of GEM and hyperthermia in unresectable gallbladder cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
response rate
survival time, progression-free survival time, safety, performance status
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
One cycle of the chemotherapy regimen consist of a drip infusion of 1000mg/m2 of GEM weekly for 3 weeks and 1 week off, and this was repeated every 4 weeks. Patients receive hyperthermia once per week, each session is scheduled for the day after administratin of GEM, employing radio frequency capacitive heating; Thermotron RF8. The duration of heating session is from 40 minutes to 60 minutes.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Eligible criteria in this study are as follows:
1.Histologically confirmed unresectable gallbladder cancer
2.Existing measurable lesion(more than two times thickness slice resolution with CT)
3.Over 20, and under 80 years of age
4.Without active other malignancy
5.No prior treatment(radiation therapy,chemotherapy,immunotherapy) for gallbladder cancer
6.PS is 0, 1 or 2
7.Sufficient functions of main organ (bone marrow, kidney, heart)
8.Without severe complications or inadequate physical condition, as diagnosed by primary physician
9.Written informed consent
Exclusion criteria in this study are as follows:
1. Interstitial pneumonitis, pulmonary fibrosis with radiological findings
2.Presence of uncontrolled diabetes, severe liver dysfunction, unstable angina, myocardial infarction within three months.
3.Presence of active severe infection
4.Pregnant, lactating women or women with suspected pregnancy.
5.Medical history of severe hypersensitivity.
6.Severe complications
7.Inappropriate patients for this study judged by the physicians.
30
1st name | |
Middle name | |
Last name | Satoshi Kokura |
Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Molecular Gastroenterology and Hepatology
Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5519
s-kokura@koto.kpu-m.ac.jp
1st name | |
Middle name | |
Last name | Satoshi Kokura |
Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Molecular Gastroenterology and Hepatology
Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5519
s-kokura@koto.kpu-m.ac.jp
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Self funding
Japan
Hyakumanben clinic
Hyakumanben clinic
NO
2009 | Year | 12 | Month | 03 | Day |
Unpublished
Terminated
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2012 | Year | 03 | Month | 01 | Day |
2009 | Year | 12 | Month | 02 | Day |
2015 | Year | 10 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002968